Based in Ann Arbor, Michigan, RetroSense Therapeutics is a biotech company focused on developing life-enhancing gene therapies to restore vision in patients with retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). With no FDA-approved drugs available for these conditions, RetroSense's pioneering approach utilizes optogenetics and channelrhodopsin-2, a photosensitivity gene from blue-green algae, to restore light sensitivity and functional vision in animal models. Founded in 2009, the company has secured exclusive global rights to relevant intellectual property from Wayne State University and Salus University. Operating virtually, RetroSense's experienced management team brings expertise in drug development and startup success, ensuring efficient progress in their mission to provide vision restoration solutions.